SWTX vs. BEAM, VIR, CBPO, ALLO, REPL, QGEN, RGEN, PCVX, RVMD, and EXEL
Should you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Beam Therapeutics (BEAM), Vir Biotechnology (VIR), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Replimune Group (REPL), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and Exelixis (EXEL). These companies are all part of the "medical" sector.
Beam Therapeutics (NASDAQ:BEAM) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
SpringWorks Therapeutics received 50 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 68.42% of users gave SpringWorks Therapeutics an outperform vote while only 51.25% of users gave Beam Therapeutics an outperform vote.
SpringWorks Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -37.33%. SpringWorks Therapeutics' return on equity of -15.46% beat Beam Therapeutics' return on equity.
In the previous week, SpringWorks Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 3 mentions for SpringWorks Therapeutics and 2 mentions for Beam Therapeutics. SpringWorks Therapeutics' average media sentiment score of 1.38 beat Beam Therapeutics' score of 0.91 indicating that Beam Therapeutics is being referred to more favorably in the media.
Beam Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.
99.7% of Beam Therapeutics shares are held by institutional investors. 4.2% of Beam Therapeutics shares are held by insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Beam Therapeutics has higher revenue and earnings than SpringWorks Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.
Beam Therapeutics presently has a consensus target price of $40.18, indicating a potential upside of 73.12%. SpringWorks Therapeutics has a consensus target price of $68.83, indicating a potential upside of 71.14%. Given SpringWorks Therapeutics' higher probable upside, research analysts clearly believe Beam Therapeutics is more favorable than SpringWorks Therapeutics.
Summary
Beam Therapeutics and SpringWorks Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get SpringWorks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SpringWorks Therapeutics Competitors List
Related Companies and Tools
